vs
Oil-Dri Corp of America（ODC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Oil-Dri Corp of America的1.7倍（$207.3M vs $120.5M），Oil-Dri Corp of America净利率更高（12.8% vs -62.0%，领先74.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -5.8%），Oil-Dri Corp of America自由现金流更多（$1.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 6.8%）
美国Oil-Dri公司是专业吸附剂及黏土基产品生产商，主营工业溢油清理吸附材料、猫砂等宠物护理产品、农业土壤改良剂及运动场场地调理材料，客户覆盖北美及全球多个商业领域。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ODC vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.5M | $207.3M |
| 净利润 | $15.5M | $-128.6M |
| 毛利率 | 29.5% | — |
| 营业利润率 | 14.1% | -54.7% |
| 净利率 | 12.8% | -62.0% |
| 营收同比 | -5.8% | 25.9% |
| 净利润同比 | -5.6% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $120.5M | $207.3M | ||
| Q3 25 | $125.2M | $159.9M | ||
| Q2 25 | $115.5M | $166.5M | ||
| Q1 25 | $116.9M | $139.3M | ||
| Q4 24 | $127.9M | $164.6M | ||
| Q3 24 | $113.7M | $139.5M | ||
| Q2 24 | $106.8M | $147.0M | ||
| Q1 24 | $105.7M | $108.8M |
| Q4 25 | $15.5M | $-128.6M | ||
| Q3 25 | $13.1M | $-180.4M | ||
| Q2 25 | $11.6M | $-115.0M | ||
| Q1 25 | $12.9M | $-151.1M | ||
| Q4 24 | $16.4M | $-133.2M | ||
| Q3 24 | $8.5M | $-133.5M | ||
| Q2 24 | $7.8M | $-131.6M | ||
| Q1 24 | $12.4M | $-170.7M |
| Q4 25 | 29.5% | — | ||
| Q3 25 | 27.8% | — | ||
| Q2 25 | 28.6% | — | ||
| Q1 25 | 29.5% | — | ||
| Q4 24 | 31.9% | — | ||
| Q3 24 | 29.0% | — | ||
| Q2 24 | 28.2% | — | ||
| Q1 24 | 29.3% | — |
| Q4 25 | 14.1% | -54.7% | ||
| Q3 25 | 12.5% | -106.9% | ||
| Q2 25 | 12.0% | -64.8% | ||
| Q1 25 | 15.0% | -102.6% | ||
| Q4 24 | 16.6% | -74.3% | ||
| Q3 24 | 11.3% | -94.6% | ||
| Q2 24 | 9.8% | -79.1% | ||
| Q1 24 | 14.4% | -151.9% |
| Q4 25 | 12.8% | -62.0% | ||
| Q3 25 | 10.4% | -112.8% | ||
| Q2 25 | 10.1% | -69.0% | ||
| Q1 25 | 11.1% | -108.5% | ||
| Q4 24 | 12.8% | -80.9% | ||
| Q3 24 | 7.5% | -95.7% | ||
| Q2 24 | 7.3% | -89.5% | ||
| Q1 24 | 11.7% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $42.4M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $266.5M | $-80.0M |
| 总资产 | $380.7M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $42.4M | $421.0M | ||
| Q3 25 | $50.5M | $202.5M | ||
| Q2 25 | $36.5M | $176.3M | ||
| Q1 25 | $22.6M | $127.1M | ||
| Q4 24 | $12.5M | $174.0M | ||
| Q3 24 | $23.5M | $150.6M | ||
| Q2 24 | $46.8M | $480.7M | ||
| Q1 24 | $27.8M | $112.3M |
| Q4 25 | $266.5M | $-80.0M | ||
| Q3 25 | $259.1M | $9.2M | ||
| Q2 25 | $246.9M | $151.3M | ||
| Q1 25 | $235.9M | $144.2M | ||
| Q4 24 | $224.0M | $255.0M | ||
| Q3 24 | $210.6M | $346.8M | ||
| Q2 24 | $202.9M | $432.4M | ||
| Q1 24 | $196.0M | $140.3M |
| Q4 25 | $380.7M | $1.5B | ||
| Q3 25 | $391.7M | $1.2B | ||
| Q2 25 | $369.5M | $1.3B | ||
| Q1 25 | $353.7M | $1.3B | ||
| Q4 24 | $350.2M | $1.5B | ||
| Q3 24 | $354.6M | $1.5B | ||
| Q2 24 | $319.2M | $1.6B | ||
| Q1 24 | $296.2M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $10.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $1.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 1.1% | -48.6% |
| 资本支出强度资本支出/营收 | 7.5% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.67× | — |
| 过去12个月自由现金流最近4个季度 | $50.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $10.3M | $-99.8M | ||
| Q3 25 | $25.2M | $-91.4M | ||
| Q2 25 | $22.7M | $-108.3M | ||
| Q1 25 | $21.4M | $-166.5M | ||
| Q4 24 | $10.9M | $-79.3M | ||
| Q3 24 | $23.4M | $-67.0M | ||
| Q2 24 | $19.0M | $-77.0M | ||
| Q1 24 | $9.4M | $-190.7M |
| Q4 25 | $1.3M | $-100.8M | ||
| Q3 25 | $17.1M | $-92.7M | ||
| Q2 25 | $16.0M | $-110.7M | ||
| Q1 25 | $16.4M | $-167.8M | ||
| Q4 24 | $-1.9M | $-79.5M | ||
| Q3 24 | $15.1M | $-68.6M | ||
| Q2 24 | $10.8M | $-79.0M | ||
| Q1 24 | $1.9M | $-193.9M |
| Q4 25 | 1.1% | -48.6% | ||
| Q3 25 | 13.7% | -58.0% | ||
| Q2 25 | 13.8% | -66.5% | ||
| Q1 25 | 14.0% | -120.5% | ||
| Q4 24 | -1.5% | -48.3% | ||
| Q3 24 | 13.3% | -49.2% | ||
| Q2 24 | 10.1% | -53.7% | ||
| Q1 24 | 1.8% | -178.2% |
| Q4 25 | 7.5% | 0.5% | ||
| Q3 25 | 6.5% | 0.8% | ||
| Q2 25 | 5.8% | 1.5% | ||
| Q1 25 | 4.3% | 1.0% | ||
| Q4 24 | 10.0% | 0.1% | ||
| Q3 24 | 7.3% | 1.2% | ||
| Q2 24 | 7.7% | 1.4% | ||
| Q1 24 | 7.1% | 3.0% |
| Q4 25 | 0.67× | — | ||
| Q3 25 | 1.93× | — | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | 1.66× | — | ||
| Q4 24 | 0.67× | — | ||
| Q3 24 | 2.74× | — | ||
| Q2 24 | 2.44× | — | ||
| Q1 24 | 0.76× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ODC
| Cat Litter | $64.6M | 54% |
| Fluids Purification | $26.7M | 22% |
| Agriculturaland Horticultural | $12.9M | 11% |
| Industrialand Sports | $11.6M | 10% |
| Animal Healthand Nutrition | $4.7M | 4% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
